BACKGROUND: Krebs von den Lungen-6 (KL-6) was suggested as ILD biomarker including idiopathic pulmonary fibrosis (IPF). Lung cancer is one of the most severe comorbidity of IPF patients. This study aims to serially analyze KL-6 in IPF patients after 24 months of Nintedanib and to first investigate the biomarker behavior in IPF associated with adenocarcinoma. MATERIALS AND METHODS: One hundred and forty-two ILD patients (median (IQR), 69 (63-75) years; 86 males) were retrospectively enrolled. Serial serum samples were collected from IPF patients before starting antifibrotic therapy and after 12 months. Serum KL-6 levels were measured by KL-6 reagent assay (Fujirebio Europe, UK). RESULTS: Increased KL-6 concentrations were identified in IPF-LC patients than IPF, fibrotic hypersensitivity pneumonitis, and pulmonary fibrosis associated with autoimmune disease groups. A cut-off value was calculated to distinguish IPF and IPF-LC patients. IPF patients monitored for 24 months with Nintedanib showed persisted increased levels of KL-6 with a progressive decline of FVC percentages. CONCLUSION: This preliminary study offers a first demonstration that very high serum concentrations of KL-6 in IPF-LC patients are associated with poor prognosis. Moreover, serial evaluation of serum KL-6 in IPF patients over 24 months of Nintedanib treatment revealed that most patients experienced a stabilization of lung function parameters and of serum concentrations of KL-6.
BACKGROUND:Krebs von den Lungen-6 (KL-6) was suggested as ILD biomarker including idiopathic pulmonary fibrosis (IPF). Lung cancer is one of the most severe comorbidity of IPF patients. This study aims to serially analyze KL-6 in IPF patients after 24 months of Nintedanib and to first investigate the biomarker behavior in IPF associated with adenocarcinoma. MATERIALS AND METHODS: One hundred and forty-two ILDpatients (median (IQR), 69 (63-75) years; 86 males) were retrospectively enrolled. Serial serum samples were collected from IPF patients before starting antifibrotic therapy and after 12 months. Serum KL-6 levels were measured by KL-6 reagent assay (Fujirebio Europe, UK). RESULTS: Increased KL-6 concentrations were identified in IPF-LCpatients than IPF, fibrotic hypersensitivity pneumonitis, and pulmonary fibrosis associated with autoimmune disease groups. A cut-off value was calculated to distinguish IPF and IPF-LCpatients. IPF patients monitored for 24 months with Nintedanib showed persisted increased levels of KL-6 with a progressive decline of FVC percentages. CONCLUSION: This preliminary study offers a first demonstration that very high serum concentrations of KL-6 in IPF-LCpatients are associated with poor prognosis. Moreover, serial evaluation of serum KL-6 in IPF patients over 24 months of Nintedanib treatment revealed that most patients experienced a stabilization of lung function parameters and of serum concentrations of KL-6.
Entities:
Keywords:
Krebs von den Lungen-6; antifibrotic therapies; idiopathic pulmonary fibrosis; lung cancer; pulmonary fibrosis associated with autoimmune diseases
Authors: Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann Journal: Am J Respir Crit Care Med Date: 2011-03-15 Impact factor: 21.405
Authors: Lucia Vietri; David Bennett; Paolo Cameli; Laura Bergantini; Giuseppe Cillis; Piersante Sestini; Elena Bargagli; Paola Rottoli Journal: Respir Investig Date: 2019-04-26
Authors: Miriana d'Alessandro; Paolo Cameli; Rosa Metella Refini; Laura Bergantini; Valerio Alonzi; Nicola Lanzarone; David Bennett; Giuseppe Domenico Rana; Francesca Montagnani; Sabino Scolletta; Federico Franchi; Bruno Frediani; Serafina Valente; Maria Antonietta Mazzei; Francesco Bonella; Elena Bargagli Journal: J Med Virol Date: 2020-06-09 Impact factor: 2.327
Authors: L Bergantini; E Bargagli; M d'Alessandro; R M Refini; P Cameli; L Galasso; C Scapellato; F Montagnani; S Scolletta; F Franchi; S Valente; D Bennett; G Sebastiani; B Frediani; F Dotta Journal: Cytokine Date: 2021-01-28 Impact factor: 3.861
Authors: Miriana d'Alessandro; Laura Bergantini; Dalila Cavallaro; Sara Gangi; Paolo Cameli; Edoardo Conticini; Bruno Frediani; Francesco Dotta; Elena Bargagli Journal: Int J Environ Res Public Health Date: 2022-02-15 Impact factor: 3.390
Authors: Miriana d'Alessandro; Edoardo Conticini; Laura Bergantini; Paolo Cameli; Luca Cantarini; Bruno Frediani; Elena Bargagli Journal: Life (Basel) Date: 2022-02-20
Authors: Edoardo Conticini; Miriana d'Alessandro; Laura Bergantini; Diego Castillo; Paolo Cameli; Bruno Frediani; Luca Cantarini; Elena Bargagli Journal: Biology (Basel) Date: 2022-01-08